Premium
Ranitidine influences the uptake of oral midazolam.
Author(s) -
Elwood RJ,
Hildebrand PJ,
Dundee JW,
Collier PS
Publication year - 1983
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1983.tb01559.x
Subject(s) - ranitidine , midazolam , bioavailability , crossover study , pharmacology , oral administration , medicine , benzodiazepine , drug interaction , plasma concentration , plasma levels , anesthesia , pharmacokinetics , receptor , sedation , pathology , placebo , alternative medicine
In a randomised crossover study in volunteers plasma midazolam levels were estimated for 24 h following 15 mg by mouth, either preceded by no medication or following 24 h therapy with ranitidine. Administration of the H2‐receptor blocker significantly increased bioavailability of the benzodiazepine and resulted in higher plasma levels for the first 6 h after taking midazolam. This was accompanied by a greater soporific effect.